Bortezomib, a proteasome inhibitor, induces apoptosis in CC cells [90] and enables IFN‐γ‐activated RIP1 kinase‐dependent necrosis in renal cell carcinoma by inhibiting NF‐κB [91]. The gene discussed is NFKB1; the disease is cholangiocarcinoma.